NASDAQ · THAR
Healthcare · Biotechnology
$3.54
Up+$0.22 (+6.63%)
Updated Aug 22, 2026, 10:43 PM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
THAR does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning THAR.
THAR research
Company profile and research snapshot.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 6, 2024 | Rodman & Renshaw | Buy | — |
No generated briefing is available yet.
Benzinga · Feb 17, 2026
Established in November 2025 through a $545 million private placement, the Company executes a differentiated digital asset treasury strategy that seeks to drive value through initiatives including Canton Coin
Benzinga · Feb 6, 2026
Leadership Expansion Supports Execution of Canton Network Infrastructure StrategyFormer DRW and Citadel Leader Joins as COO to Drive Institutional Platform ExpansionNEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc.
SeekingAlpha · Jan 28, 2026
SeekingAlpha · Jan 23, 2026
Tharimmune (THAR) builds a Canton Coin digital asset treasury with $545 million raised. Read here for a detailed investment analysis.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning THAR.
